SCHEMBL4157927

SCHEMBL4157927

Nc1ccc2nc(-c3ccc(Br)cc3)cn2c1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.69
RAB9A P51151 7/20 0.69
APP P05067 6/20 0.69
PAX8 Q06710 2/20 0.69
ALDH1A1 P00352 6/20 0.63
KDM4E B2RXH2 4/20 0.59
POLB P06746 2/20 0.59
SMN1; SMN2 Q16637 3/20 0.58
GAA P10253 1/20 0.58
MEN1 O00255 2/20 0.53
KMT2A Q03164 2/20 0.53
MITF O75030 1/20 0.53
KDM5A P29375 1/20 0.53
KDM5C P41229 1/20 0.53
LMNA P02545 1/20 0.52
NFKB1 P19838 1/20 0.52
NFKB2 Q00653 1/20 0.52
RELA Q04206 1/20 0.52
ALDH1A3 P47895 4/20 0.51
ALDH1A2 O94788 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5776511 0.90 APP (0.67) NPC1RAB9AAPPPAX8ALDH1A1
SCHEMBL2127350 0.90 APP (0.69) NPC1RAB9AAPPPAX8ALDH1A1
SCHEMBL7605200 0.86 NPC1 (0.77) NPC1RAB9AAPPPAX8ALDH1A1
Bromide SCHEMBL1691457 0.84 NPC1 (0.75) NPC1RAB9AAPPPAX8ALDH1A1
SCHEMBL12380447 0.83 NPC1 (0.61) NPC1RAB9AAPPPAX8ALDH1A1
SCHEMBL2127137 0.83 ALDH1A3 (0.65) NPC1RAB9AAPPPAX8ALDH1A1
SCHEMBL4781380 0.83 RAB9A (0.75) NPC1RAB9AAPPPAX8ALDH1A1
SCHEMBL27188296 0.83 ALDH1A3 (0.69) NPC1RAB9AAPPPAX8ALDH1A1
SCHEMBL973527 0.81 NPC1 (1.00) NPC1RAB9AAPPPAX8ALDH1A1
SCHEMBL26603206 0.80 APP (0.69) NPC1RAB9AAPPPAX8ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250101018-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2025-03-27 US disclosed
US-12116364-B2 Heteroaryl compounds and uses thereof APRINOIA THERAPEUTICS INC. (CN) 2024-10-15 US disclosed
US-20230374006-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2023-11-23 US disclosed
US-20230374006-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2023-11-23 US disclosed
US-20230374006-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS LIMITED (CN) 2023-11-23 US disclosed
CN-112384517-B Heteroaryl compounds and uses thereof 新旭生技股份有限公司 2023-07-14 CN disclosed
US-20230047178-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2023-02-16 US disclosed
US-20230047178-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2023-02-16 US disclosed
US-20210253569-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2021-08-19 US disclosed
US-20210253569-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2021-08-19 US disclosed
WO-2019214681-A1 HETEROARYL COMPOUNDS AND USES THEREOF APRINOIA THERAPEUTICS INC. (CN) 2019-11-14 WO disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds CORFIELD JOHN ANDREW 2009-05-28 US disclosed
EP-1971599-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SmithKline Beecham Corporation (US) 2008-09-24 EP disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 WO disclosed
WO-2007071434-A1 ANTIVIRAL 2-CARBOXY-THIOPHENE COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2007-06-28 WO disclosed
WO-2007039146-A1 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-12 WO disclosed
WO-2007039146-A1 4-CARBOXY PYRAZOLE DERIVATIVES AS ANTI-VIRAL AGENTS SMITHKLINE BEECHAM CORPORATION (US) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374006-A1 HETEROARYL COMPOUNDS AND USES THEREOF MAPT, APP, SLCO1B3 NPC1 88/4885RAB9A 603/4885APP 2/4885
US-20210253569-A1 HETEROARYL COMPOUNDS AND USES THEREOF MAPT, APP, SLCO1B3 NPC1 88/4885RAB9A 603/4885APP 2/4885
US-20230047178-A1 HETEROARYL COMPOUNDS AND USES THEREOF MAPT, APP, SLCO1B3 NPC1 88/4885RAB9A 603/4885APP 2/4885
US-20090136448-A1 Antiviral 2-Carboxy-Thiophene Compounds EIF2AK2, HAVCR2, MAVS NPC1 1833/4885RAB9A 1920/4885APP 4884/4885
US-20250101018-A1 HETEROARYL COMPOUNDS AND USES THEREOF MAPT, APP, SLCO1B3 NPC1 88/4885RAB9A 603/4885APP 2/4885
US-12116364-B2 Heteroaryl compounds and uses thereof MAPT, APP, SLCO1B3 NPC1 88/4885RAB9A 603/4885APP 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.